Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Highly conserved epitopes of Zika envelope glycoprotein may act as a novel peptide vaccine with high coverage: Immunoinformatics approach
10th Euro Global Summit and Expo on Vaccines & Vaccination
June 16-18, 2016 Rome, Italy

Marwan Mustafa Badawi Suluiman, Marwa Mohamed Osman, Afra Abd Elhamid Fadl Alla, Ammar Mohammed Ahmedani, Mohamed hamed Abdalla, Mosab Mohamed Gasemelseed, Ahmed Abubakar Elsayed and Mohamed Ahmed Salih

Africa City of Technology, Sudan
Al Neelain University, Sudan
Soba University Hospital, Sudan

Posters & Accepted Abstracts: J Vaccines Vaccin

Abstract:

Zika virus (ZIKV) is positive sense single stranded RNA of Flavivirus genus belonging to the Flaviviridae family. It has neither drug nor protective vaccine and thought to be in relatedness to neurological diseases such as Guillain Barre Syndrome and microcephaly in neonates of infected mothers. The aim of this study is to analyze envelope glycoprotein-E of all Zika strains using in silico approaches looking for conservancy which is further studied to predict all potential epitopes that can be used after in vitro and in vivo confirmation as a therapeutic peptide vaccine. A total of 50 Zika virus variants�?? (include 12 from South America) polyproteins retrieved from NCBI database were aligned and the conserved regions of envelope glycoprotein-E were selected for epitopes prediction. We used IEDB analysis resource to predict B and T-cell epitopes and to calculate the population coverage. Epitopes with high scores in both B-cell and T-cell epitopes predicting tools were suggested. Three epitopes were proposed for international therapeutic peptide vaccine for B-cell (AQDKP, TPNSPRAE and TPHWNNK) and two other epitopes designed especially for South America strains (LDKQSDTQYV and EVQYAGTDGPCK). For T-cell epitopes, MMLELDPPF epitope was highly recommended as therapeutic peptide vaccine to interact with MHC class I along with three other epitopes (MAVLGDTAW, KEWFHDIPL and DTAWDFGSV) which showed very good population coverage against the whole world population. Three epitopes showed high affinity to interact with MHC class II alleles (FKSLFGGMS, LITANPVIT and VHTALAGAL) with excellent population coverage throughout the world and South America region. Herd immunity protocols can be achieved in countries with low population coverage percentage to minimize the active transmission of the virus, especially among pregnant women and other groups at risk. We recommend in vitro and in vivo proving the effectiveness of these proposed epitopes as a vaccine as well as to be used as a diagnostic screening test.

Biography :

Marwan Mustafa Badawi Suluiman is currently a Master degree student of Medical Microbiology.

Email: mmbadwi44new@gmail.com